Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5926371 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GSK5926371 | EXPERIMENTAL | - |
| Part 1: Dose Escalation of GSK5926371 | EXPERIMENTAL | - |
| Part 2: Dose Division of GSK5926371 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5926371 | DRUG | GSK5926371 will be administered at different dose levels. |
Inclusion Criteria: * Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated, 1. Has measurable disease, 2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for th...
GSK5926371 is an investigational small molecule being studied for the treatment of Systemic Lupus Erythematosus and relapsed or refractory B-cell Non-Hodgkin Lymphoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
GSK5926371 is being studied in B-cell driven autoimmune rheumatic diseases and B-cell Non-Hodgkin Lymphoma, indicating it targets pathways involved in B-cell function. The specific molecular target has not been disclosed in available information.
GSK5926371 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and clinical activity.
GSK5926371 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. Two Phase 1 trials are listed, one recruiting and one not yet recruiting.
GSK5926371 is being studied in two Phase 1 trials. NCT07371468 is recruiting participants with Systemic Lupus Erythematosus in multiple countries. NCT07607925 is not yet recruiting and will evaluate the drug in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
No alternative names for GSK5926371 have been disclosed. The drug is identified solely by its compound number GSK5926371 in clinical trial registrations and available information.